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Serum Concentration of HDL 
Particles Predicts Mortality in Acute 
Heart Failure Patients
Ines Potočnjak1, Vesna Degoricija1,2, Matias Trbušić1,2, Gudrun Pregartner3, Andrea Berghold3, 
Gunther Marsche4,5 & Saša Frank5,6
Clinical studies have shown that assessing circulating concentrations of high-density lipoprotein 
(HDL) particles by nuclear magnetic resonance (NMR) spectroscopy is superior to HDL-cholesterol in 
predicting cardiovascular risk. We tested the hypothesis that circulating concentrations of HDL particles 
predict 3-month mortality of patients with acute heart failure (AHF). Out of 152 included patients, 52% 
were female, additionally the mean patient age was 75.2 ± 10.3 years, and three-month mortality was 
27%. Serum lipoprotein profile at admission was determined by NMR spectroscopy. Univariate logistic 
regression analyses revealed a significant inverse association of total (odds ratio (OR) 0.38 per 1-SD 
increase, 95% confidence interval (CI) 0.23–0.60, p < 0.001) and small HDL particle concentrations (OR 
0.35 per 1-SD increase, 95% CI 0.19–0.60, p < 0.001) with 3-month mortality, whereas concentrations 
of large HDL particles (p = 0.353) or HDL-cholesterol (p = 0.107) showed no significant association. 
After adjustment for age, sex, mean arterial pressure, low-density lipoprotein cholesterol, glomerular 
filtration rate, urea, and N-terminal pro-brain natriuretic peptide, both the total and small HDL particle 
concentrations remained significantly associated with 3-month mortality. Based on our results, we 
conclude that total and small HDL particle concentrations strongly and independently predict 3-month 
mortality in AHF patients.
Heart failure (HF) remains an important cause of morbidity and mortality worldwide1. Accurate prognostic bio-
markers are crucial for risk assessment, timely and appropriate therapeutic intervention, and overall management 
of HF. Therefore, identification of new markers reflecting different aspects of the underlying pathophysiology may 
improve risk assessment in HF.
High-density lipoprotein (HDL) exerts numerous beneficial effects on the cardiovascular system. These 
include attenuation of the inflammatory response in the vascular endothelium and macrophages, low-density 
lipoprotein (LDL) protection from oxidation, endothelial nitric oxide (NO) production stimulation and the asso-
ciated vasodilatation promotion, as well as insulin-independent glucose uptake stimulation in cardiomyocytes2–6.
The promotion of reverse cholesterol transport is the best-studied protective activity of HDL. It is a dynamic 
process by which cholesterol is transported by HDL from the periphery to the liver for excretion7. Recent studies 
delivered solid evidence that cholesterol efflux capacity is inversely related to incident coronary heart events in 
the general population, independent of well-known cardiovascular risk factors8,9. However, it has to be pointed 
out that this association is not present in patients with chronic kidney disease10.
Even though clinical and epidemiological studies revealed an inverse relationship between HDL-cholesterol 
and cardiovascular disease11, a number of studies argue against HDL-cholesterol as therapeutic target. This thesis 
was exemplified by a failure of the Mendelian randomization approach to show a relationship between genetic 
variants that increase plasma concentrations of HDL cholesterol and a decreased risk of cardiovascular events12 
as well as by a failure of pharmacological HDL-cholesterol raising therapy to reduce cardiovascular events13,14. 
HDL-cholesterol concentrations, therefore, appear to provide limited information regarding the cardioprotective 
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activities of HDL, despite increasing evidence supporting the clinical significance of these pleiotropic HDL 
functions.
Decreased HDL cholesterol plasma levels and impaired HDL function have previously been reported 
in HF patients15, and several studies examined the association of outcome and prognosis in HF with 
HDL-cholesterol16–18.
Clinical studies have shown that assessing circulating concentrations of HDL particles by nuclear magnetic 
resonance (NMR) spectroscopy is superior to HDL-cholesterol in predicting cardiovascular risk19. HDL particle 
concentrations attribute equal weight to all HDL subclasses and therefore better represent the biological rela-
tionship between HDL and clinical risk19. While assessing the functional properties of HDL may not be readily 
applicable in the everyday clinical practice, NMR-based measurements of HDL particle concentrations bear a 
great potential for improved assessment of cardiovascular risk.
We hypothesized that HDL particle concentration might predict mortality in subjects presenting with acute 
heart failure (AHF). Therefore, we explored the association of HDL particle concentrations with 3-month mor-
tality in patients with AHF.
Results
Patients. The patients’ baseline characteristics were reported elsewhere20. In brief, out of 152 included 
patients 52% were female, 7.2% belonged to New York Heart Association Functional Classification (NYHA) class 
2, 54.6% belonged to NYHA class 3, and 38.2% belonged to NYHA class 4. The mean patient age was 75.2 ± 10.3 
years. Frequent comorbidities were hypertension (89.5%), followed by type 2 diabetes mellitus (51.7%), hyperlipi-
demia/hypertriglyceridemia (39.5%), and hypercholesterolemia (38.8%). Worsening of chronic HF emerged in 
69.1% of patients, and 42.4% had a preserved ejection fraction. Three-month mortality was 27.4%. The patients’ 
laboratory parameters are shown in Table 1.
Correlation of HDL particle- and HDL cholesterol- concentrations with laboratory and clini-
cal variables. As presented in Table 2, the concentrations of total and small HDL particles were positively 
correlated with albumin and glomerular filtration rate (GFR) and negatively correlated with urea, N-terminal 
pro-Brain Natriuretic Peptide (NT-proBNP), and C-reactive protein (CRP). Concentrations of large HDL par-
ticles were not significantly correlated with any laboratory parameters, whereas levels of HDL-cholesterol were 
positively correlated with GFR and negatively correlated with urea and CRP. The concentrations of large HDL 
particles were negatively correlated with body weight and body mass index (BMI), a correlation that was observed 
neither for the concentrations of total and small HDL particles nor for HDL- cholesterol (Table 2).
Variable n
Total cholesterol (mmol/L) 152 3.8 [1.7–9.1]
LDL-c (mmol/L) 152 2.3 [0.8–6.3]
HDL-c (mmol/L) 152 1.0 [0.3–3.6]
Triglycerides (mmol/L) 152 1.1 [0.5–4.3]
Large VLDL-p (nmol/L) 76 2.4 [1.5–10.6]
Total LDL-p (μ mol/L) 135 1.1 [0.4–2.5]
Large LDL-p (μ mol/L) 126 0.7 [0.3–2.1]
Small LDL-p (μ mol/L) 132 0.5 [0.2–1.4]
Total HDL-p (μ mol/L) 135 21.0 [3.7–37.5]
Large HDL-p (μ mol/L) 108 5.7 [2.8–14.9]
Small HDL-p (μ mol/L) 115 17.0 [6.3–34.2]
VLDL size (nm) 135 47.1 [37.1–52.3]
LDL size (nm) 135 21.2 [20.2–22.7]
HDL size (nm) 135 9.2 [8.3–10.6]
CRP (μ g/mL) 150 9.4 [0.2–247.4]
Albumin (g/L) 149 40.0 [21.0–72.0]
Protein (g/L) 149 68.0 [31.0–87.0]
Urea (mmol/L) 151 8.0 [3.0–64.0]
Creatinine (μ mol/L) 151 106.0 [53.0–273.0]
GFR (mL/min/1.73 m2) 151 50.9 [15.0–105.7]
NT-proBNP (pg/mL) 141 9570.0 [171.0–70000.0]
Table 1.  Laboratory parameters. Results are presented as median, minimum and maximum. 
CRP = C-reactive protein; GFR = glomerular filtration rate; HDL-c = high-density lipoprotein cholesterol; 
HDL-p = HDL particle concentration; LDL-c = low-density lipoprotein cholesterol; LDL-p = LDL particle 
concentration; n = number of samples in which particular parameter was analysed; NT-proBNP = N-terminal 
pro-Brain Natriuretic Peptide; VLDL-p = very low-density lipoprotein particle concentration.
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Logistic regression analyses. Univariate analyses revealed a highly significant inverse associa-
tion of 3-month mortality with total and small HDL particle concentrations as well as with total cholesterol, 
LDL-cholesterol, mean arterial pressure (MAP), and GFR (Table 3). A significant positive association with 
3-month mortality was observed for creatinine, urea, and NT-proBNP (Table 3). Concentrations of large HDL 
particles were not significantly associated with 3-month mortality (Table 3). Importantly, the concentrations of 
both total and small HDL particles remained significantly associated with 3-month mortality after adjusting for 
age and sex, as well as for clinical and laboratory parameters that showed a significant association with 3-month 
mortality in the univariate analyses, taking multicollinearity into account (Table 4).
Discussion
Accurate prognostic biomarkers are critical for risk assessment, appropriate therapeutic intervention, and over-
all management of HF. The present study shows for the first time that a low concentration of circulating small 
HDL particles is associated with 3-month mortality of AHF patients. Interestingly, only the concentrations of 
small HDL particles were associated with mortality, whereas the concentrations of large HDL particles and 
HDL-cholesterol were not.
Our results appear to be in line with recent studies showing that elevated concentrations of HDL particles were 
associated with a reduced risk of coronary heart disease (CHD) as well as with reduced CHD mortality [reviewed 
in21]. However, as mentioned above, no single study so far has examined the role of HDL particle concentrations 
on mortality in AHF. Previous studies have clearly shown that cardioprotective activities of HDL, including cho-
lesterol efflux capacity, anti-inflammatory, anti-apoptotic, as well as endothelial protective capabilities, depend on 
specific HDL particle characteristics that are not well represented by the HDL-cholesterol content (a measure of 
larger, more cholesterol-rich HDL subclasses)21,22. The results of the present study appear to be in agreement with 
the concept of a strong structure-function relationship of HDL particles.
Our results clearly demonstrate that circulating HDL particle concentrations, but not the levels of 
HDL-cholesterol, predict 3-month mortality of AHF patients. Interestingly, serum concentrations of total and 
small HDL particles, but not of HDL-cholesterol, were positively correlated with the albumin level, a marker 
of nutritional status and liver biosynthetic capacity, and negatively correlated with NT-proBNP, a marker of HF 
severity (Table 2). This difference between small HDL particles and HDL-cholesterol regarding their sensitivity 
to the AHF pathophysiology could be explained by the fact that circulating HDL-cholesterol levels mainly reflect 
the concentrations of large (cholesterol-rich) HDL particles. Our observation that neither HDL-cholesterol nor 
the concentrations of large HDL particles were correlated with albumin or NT-proBNP levels (Table 2) is in full 
agreement with that notion.
In line with previous studies21, small HDL particles constituted the majority of total HDL particles (Table 1). In 
the present study, the concentration of small HDL particles differed markedly from that of the less abundant large 
Large HDL-p (μmol/L) Small HDL-p (μmol/L) Total HDL-p (μmol/L) HDL-c (mmol/L)
Albumin (g/L)
ρ − 0.12 0.23 0.28 0.02
p 0.223 0.012 0.001 0.787
n 105 114 132 149
Urea (mmol/L)
ρ − 0.05 − 0.22 − 0.31 − 0.24
p 0.608 0.019 <0.001 0.003
n 107 114 134 151
GFR (mL/min/1.73 m2)
ρ 0.08 0.27 0.25 0.17
p 0.398 0.003 0.004 0.037
n 107 114 134 151
NT-proBNP (pg/mL)
ρ 0.07 − 0.31 − 0.44 − 0.16
p 0.478 0.001 <0.001 0.061
n 104 11 129 141
CRP (μg/mL)
ρ − 0.12 − 0.28 − 0.43 − 0.28
p 0.231 0.003 <0.001 <0.001
n 106 113 133 150
Body weight (kg)
ρ − 0.29 0.12 0.1 − 0.12
p 0.002 0.197 0.233 0.138
n 108 115 135 152
BMI (kg/m2)
ρ − 0.28 0.18 0.15 − 0.11
p 0.003 0.056 0.089 0.197
n 108 115 135 152
Table 2.  Correlation analyses of HDL particle- and HDL cholesterol- concentrations with laboratory and 
clinical parameters. Data are presented as Spearman correlation coefficient, p-value and number of samples; 
significant associations are depicted in bold. CRP = C-reactive protein; GFR = glomerular filtration rate; 
HDL-c = high-density lipoprotein cholesterol; HDL-p = HDL particle concentration; n = number of samples 
in which correlation was analysed; NT-proBNP = N-terminal pro-Brain Natriuretic Peptide; p = p value; 
ρ = Spearman correlation coefficient.
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HDL particles, regarding their associations with serum albumin, the markers of renal function, urea, and GFR, as 
well as with the inflammatory marker CRP or with NT-proBNP (Table 2). A previous study showed that adiposity 
affects lipoprotein size and subclass concentrations in the general population23. We also observed that the con-
centrations of large, but not small, HDL particles were negatively correlated with the body mass index (Table 2). 
Strikingly, we found no correlation between the serum levels of small and large HDL particles (ρ = − 0.16; 
p = 0.132). This observation suggests that in AHF patients the metabolism of small and large HDL particles is not 
linked. Our results are in agreement with a recent metabolic study showing that the liver directly secrets HDL 
particles of different sizes into the circulation, whereas the interconversion of circulating HDL particles appears 
to be of minor importance24.
Circulating HDL particles may exert direct positive effect on the failing heart. HDL has been shown to atten-
uate apoptosis, improve cell survival, preserve mitochondrial function, attenuate oxidative stress25,26, as well as to 
promote glucose uptake by cardiomyocytes27. Furthermore, by inducing the expression and activity of endothe-
lial nitric oxide synthase, HDL increases vascular NO bioavailability5, thereby promoting vasorelaxation of the 
coronary arteries and, in turn, perfusion of the failing heart. By attenuation of the endothelial inflammatory 
response3, as well as by endotoxin-binding and neutralization, HDL may ameliorate the chronic inflammatory 
status in HF28. In line with this, we found a negative correlation of HDL particle concentrations and CRP in our 
AHF cohort (Table 2).
Based on our results, we conclude that serum concentrations of total and small HDL particles are strong and 
independent predictors of 3-month mortality in AHF patients.
Variable Category OR (95% CI) per 1 SD p-value Events
Age (years) 1.37 (0.94–2.08) 0.114 40/146
Sex male Ref. 16/70
female 1.56 (0.75–3.30) 0.239 24/76
BMI (kg/m2) 0.70 (0.47–1.02) 0.074 40/146
Hypertension no Ref. 7/16
yes 0.44 (0.15–1.31) 0.128 33/130
Type 2 Diabetes Mellitus no Ref. 21/69
yes 0.76 (0.36–1.58) 0.465 19/76
MAP (mmHg) 0.56 (0.36–0.84) 0.007 40/146
NYHA class 2 and 3 Ref 20/90
4 1.94 (0.93–4.09) 0.078 20/56
EF (%)* > 40 Ref 14/71
≤ 40 1.44 (0.65–3.26) 0.373 17/65
Total cholesterol (mmol/L) 0.53 (0.33–0.80) 0.005 40/146
LDL-c (mmol/L) 0.56 (0.34–0.85) 0.011 40/146
HDL-c (mmol/L) 0.69 (0.43–1.05) 0.107 40/146
Triglycerides (mmol/L) 0.74 (0.46–1.10) 0.172 40/146
Large VLDL-p (nmol/L) 0.43 (0.15–0.91) 0.066 20/74
Total LDL-p (μ mol/L) 0.68 (0.44–1.02) 0.075 37/130
Large LDL-p (μ mol/L) 0.63 (0.38–0.98) 0.057 34/121
Small LDL-p (μ mol/L) 0.89 (0.58–1.30) 0.561 36/127
Total HDL-p (μ mol/L) 0.38 (0.23–0.60) <0.001 37/130
Large HDL-p (μ mol/L) 1.22 (0.79–1.88) 0.353 30/103
Small HDL-p (μ mol/L) 0.35 (0.19–0.60) <0.001 27/110
GFR (ml/min/1.73 m2) 0.60 (0.39–0.88) 0.012 39/145
Creatinine (mol/L) 1.44 (1.02–2.06) 0.039 39/145
Urea (mmol/L) 1.61 (1.13–2.39) 0.013 39/145
NT-proBNP (pg/mL) 1.92 (1.32–2.93) 0.001 38/135
CRP (μ g/mL) 1.18 (0.83–1.68) 0.341 40/145
Table 3.  Univariate logistic regression analysis of clinical and laboratory parameters, and 3-month 
mortality. For continous variables ORs are presented per standard deviation increment. Significant 
associations are depicted in bold. BMI = Body Mass Index; CI = confidence interval; CRP = C-reactive protein; 
EF = Ejection Fraction; Events = number of events/total number of patients in category; GFR = glomerular 
filtration rate; HDL-c = high density lipoprotein cholesterol; HDL-p = HDL particle concentration; 
LDL-c = low-density lipoprotein cholesterol; LDL-p = large LDL particle concentration; n = number of samples 
in which particular parameter was analysed; MAP = Mean Arterial Pressure; NT-proBNP = N-terminal 
pro-Brain Natriuretic Peptide; NYHA = New York Heart Association Functional Classification; OR = odds 
ratio; Ref. = reference category; SD = standard deviation; VLDL-p = very low-density lipoprotein particle 
concentration.
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Because the limited number of participants in this monocentric study may have affected the statistical power 
of our analyses, further large studies are needed to confirm our results.
Methods
Study design and patients. The study was designed as a prospective, single-center study. It included hos-
pitalized adult Caucasian consecutive patients with AHF. The Ethics Committee of the University Hospital Centre 
Sisters of Charity, Zagreb, Croatia as well as the Ethics Committee of the Medical University of Graz approved the 
study. Written informed consent was obtained in compliance with Good Clinical Practice, and the Declaration of 
Helsinki29. In total, 152 patients were enrolled from November 2013 to February 2015. The patients were classified 
according to the European Society of Cardiology (ESC) and the American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) Guidelines for HF30–32. All patients were treated according to the ESC 
Guidelines for AHF31,32. Hypertension was diagnosed according to the ESC criteria33. Diabetes was diagnosed 
in patients with dietary treatment, antidiabetic medication or current fasting plasma glucose levels higher than 
7.0 mmol/L34. Hypercholesterolemia was defined as LDL-cholesterol levels higher than 3.5 mmol/L, or taking a 
lipid-lowering drug and hypertriglyceridemia was defined as triglyceride levels higher than 1.7 mmol/L. Patients 
with severe renal failure (serum creatinine ≥ 400 mmol/L) were not included in the study.
Laboratory assays. Blood samples were obtained at admission to the hospital. The blood was collected 
in 6 mL tubes, VACUETTE® Z Serum Clot Activator (Greiner Bio-one GmbH, Kremsmuenster, Austria). 
Beckman Coulter instrument AU 2700, 2007 (Brea, CA, SAD) and Architect c8000, Abbott 2013 (Chicago, IL, 
SAD) were used for analysis of serum albumin, creatinine, urea, CRP, total plasma cholesterol, LDL-cholesterol, 
HDL-cholesterol, and triglycerides. GFR was calculated as previously described35. Electrochemiluminescence 
immunoassay with Elecsys e411 (Roche Diagnostics GmbH, Mannheim, Germany) was used for NT-proBNP 
quantification.
Lipoprotein profiling by NMR spectroscopy. The lipoprotein profiles of 138 serum samples were avail-
able for analysis using the AXINON® lipoFIT®-S100 test system (Numares Health, Regensburg, Germany) as 
described previously36. In brief, serum (630 μ l) was gently mixed with 70 μ l of an internal standard (with reference 
substances, NaN3 and D2O). From this solution 600 μ l were transferred into 5-mm NMR tubes, followed by the 
recording of NMR spectra at a temperature of 310 K on a shielded 600 MHz Bruker Avance III HD spectrome-
ter with a 5-mm triple resonance TXI probe head including a deuterium lock channel and a z-grade coil. Only 
samples and their spectra which met a defined set of quality criteria were analyzed, in order to ensure the data 
quality. Lipoprotein particle concentrations and mean sizes reported are calibrated to an NMR-based lipoprotein 
profiling method37. HDL particles with a diameter smaller than 8.8 nm were designated small, and those with a 
diameter of 8.8 nm or more were considered large38. The number (n) of samples, which were analyzed for a par-
ticular lipoprotein parameter, is indicated in Table 2.
Statistical analysis. Categorical data are shown as absolute and relative frequencies; continuous data are 
shown as median and range from minimum to maximum. Correlations between various laboratory/clinical 
parameters and certain lipid parameters, including concentrations of HDL particles and HDL-cholesterol, were 
determined by Spearman correlation. Univariate logistic regression analyses was used to examine the impact 
of various clinical and laboratory parameters on 3-month mortality. To further assess the predictive ability of 
the total and small HDL particle concentrations, we adjusted for age, gender, mean arterial pressure (MAP), 
LDL-cholesterol, GFR, urea, and NT-proBNP in a multivariate model. Results were expressed as odds ratio (OR) 
and the respective 95% confidence interval (CI) per standard deviation (SD) increase. Variance inflation factor 
was used to assess multicollinearity among covariates in the multivariate model. R version 3.2.2. was used to 
analyse data.
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